Holly Lofton says some patients using gray-market reta saw no weight loss at all, since those products often lack the active ingredient. UK approval is still pending.
Recap by typeshit. Full story at Women's Health.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
He lists what Japanese clinics advertise BPC-157, TB-500 and Epitalon for, and notes the FDA has flagged missing human safety data for several of them.
The companies shared aging clock data from semaglutide and tirzepatide trials at a conference. Geneticist Steve Horvath called a two year effect strong.
Loading…